Zimmer Biomet reported better-than-expected Q2 2025 results, with revenues of US$2.08 billion and adjusted EPS of US$2.07, leading management to raise full-year forecasted adjusted EPS to US$8.10–US$8.30 and reduce its anticipated tariff headwinds to about US$40 million.

Industry analysts pointed to the company's reduced tariff impact and upwardly revised guidance as factors that set Zimmer Biomet apart among peers in a strong quarter for surgical equipment and consumables.

We'll examine how Zimmer Biomet's raised 2025 earnings guidance may affect the company’s outlook for margin and revenue growth.

Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 30 best rare earth metal stocks of the very few that mine this essential strategic resource.

To be a shareholder in Zimmer Biomet, you need to believe that rising global procedure volumes and ongoing advances in surgical robotics and digital health will enable the company to capitalize on increasing demand for orthopedic solutions. The latest earnings beat, guidance raise, and easing of tariff headwinds address near-term concerns and strengthen the case for margin recovery, though pricing pressure and integration risks from recent acquisitions still remain the foremost risks to growth and profitability. The overall risk outlook is largely unchanged by these updates.

Among recent events, Zimmer Biomet’s decision to maintain its quarterly dividend at US$0.24 per share is relevant, signaling continued commitment to returning capital despite integration costs and ongoing legal challenges. Stable dividends could appeal to income-focused investors, but also highlight that further margin improvements hinge on successfully overcoming current operational headwinds.

However, with competitive threats rising in the robotics segment and market share at stake, investors should pay attention to ...

Read the full narrative on Zimmer Biomet Holdings (it's free!)

Zimmer Biomet Holdings' outlook anticipates $9.2 billion in revenue and $1.3 billion in earnings by 2028. This is based on a projected 5.5% annual revenue growth rate and an earnings increase of $476.5 million from the current $823.5 million.

Uncover how Zimmer Biomet Holdings' forecasts yield a $110.92 fair value, a 11% upside to its current price.

Simply Wall St Community members valued Zimmer Biomet between US$92.52 and US$169.48, based on four diverse viewpoints. With analysts citing persistent industry-wide pricing pressure as a key risk, there is clear room for discussion about future profit margins and growth potential.

Explore 4 other fair value estimates on Zimmer Biomet Holdings - why the stock might be worth as much as 69% more than the current price!

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

A great starting point for your Zimmer Biomet Holdings research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.

Our free Zimmer Biomet Holdings research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Zimmer Biomet Holdings' overall financial health at a glance.

Our top stock finds are flying under the radar-for now. Get in early:

Trump's oil boom is here - pipelines are primed to profit. Discover the 22 US stocks riding the wave.

Find companies with promising cash flow potential yet trading below their fair value.

These 11 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include ZBH.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com